Clinical Trial Update: Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of ARQ-252 Cream 0.3% for non-segmental facial vitiligo was terminated. The study results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• ARQ-252 Cream 0.3% (ARQ-252)

Snippet

Sponsor: Arcutis Biotherapeutics, Inc. | Conditions: Vitiligo | Phase 2 | Status: TERMINATED | Results posted: 2024-07-12